Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook
Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro ...
Stocktwits on MSN19h
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another ...